Island Pharmaceuticals Expands Antiviral Pipeline Through Strategic Burnet Institute Collaboration
Island Pharmaceuticals announced a strategic research collaboration with Australia’s Burnet Institute to evaluate its antiviral candidates ISLA‑101 and Galidesivir against additional high‑value viral threats such as measles, chikungunya, and Ross River virus. The collaboration, led by Burnet virology expert Dr. Johanna Fraser and supported by a competitive NHMRC grant, aims to generate translational data that can inform expanded development pathways aligned with biodefence, national stockpile priorities, and broader antiviral applications. 
Island Pharmaceuticals Expands Antiviral Pipeline Through Strategic Burnet Institute Collaboration